EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic

Daniel Tortorice, Rino Rappuoli iD, David E Bloom

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2321978121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Daniel Tortorice und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics and Accounting, College of the Holy Cross, Worcester, MA 01610. Hauptthemen laut MEDLINE: COVID-19, Pandemics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, International Vaccine Institute, The Davos Alzheimer's Collaborative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In response to the COVID-19 pandemic, governments directly funded vaccine research and development (R&D), quickly leading to multiple effective vaccines and resulting in enormous health and economic benefits to society. We develop a simple economic model showing this feat could potentially be repeated for other health challenges. Based on inputs from the economic and medical literatures, the model yields estimates of optimal R&D spending on treatments and vaccines for known diseases. Taking a global and societal perspective, we estimate the social benefits of such spending and a corresponding rate of return. Applications to Streptococcus A vaccines and Alzheimer’s disease treatments demonstrate the potential of enhanced research and development funding to unlock massive global health and health-related benefits. We estimate that these benefits range from 2 to 60 trillion (2020 US$) and that the corresponding rates of return on R&D spending range from 12% to 23% per year for 30 y. We discuss the current shortfall in R&D spending and public policies that can move current funding closer to the optimal level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19PandemicsHumansSARS-CoV-2Models, EconomicBiomedical ResearchCOVID-19 VaccinesCost-Benefit Analysis

Stichwörter der Autor:innen

COVID-19Group A Strephealth economicsresearch & developmentvaccines

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Economics and Accounting, College of the Holy Cross, Worcester, MA 01610.
  • Fondazione Biotecnopolo di Siena, Siena 53100, Italy.
  • Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115.

ORCID-Profile: Rino Rappuoli

Förderung

  • Wellcome Trust
  • International Vaccine Institute
  • The Davos Alzheimer's Collaborative
  • The Davos Alzheimer's Collaborative

Zitieren

APA

Tortorice, D., Rappuoli, R., & Bloom, D. E. (2024). The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2321978121

Vancouver

Tortorice D, Rappuoli R, Bloom DE. The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2321978121

BibTeX
@article{Tortorice2024,
  author = {Tortorice, Daniel and Rappuoli, Rino and Bloom, David E},
  title = {The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2321978121}
}
Kostenlos starten →